These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 24855725)

  • 1. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
    O'Sullivan CC; Swain SM
    Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
    Chung C; Lam MS
    Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertuzumab and trastuzumab: the rationale way to synergy.
    Richard S; Selle F; Lotz JP; Khalil A; Gligorov J; Soares DG
    An Acad Bras Cienc; 2016; 88 Suppl 1():565-77. PubMed ID: 27275646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
    Dawood S; Sirohi B
    Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertuzumab for the treatment of breast cancer.
    Lynce F; Swain SM
    Cancer Invest; 2014 Oct; 32(8):430-8. PubMed ID: 24921704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
    Baselga J; Swain SM
    Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab for the treatment of breast cancer: a safety review.
    Gao J; Swain SM
    Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertuzumab: development beyond breast cancer.
    Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
    Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Blumenthal GM; Scher NS; Cortazar P; Chattopadhyay S; Tang S; Song P; Liu Q; Ringgold K; Pilaro AM; Tilley A; King KE; Graham L; Rellahan BL; Weinberg WC; Chi B; Thomas C; Hughes P; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(18):4911-6. PubMed ID: 23801166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
    Amiri-Kordestani L; Wedam S; Zhang L; Tang S; Tilley A; Ibrahim A; Justice R; Pazdur R; Cortazar P
    Clin Cancer Res; 2014 Nov; 20(21):5359-64. PubMed ID: 25204553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab for the treatment of metastatic breast cancer.
    Langdon SP; Cameron DA
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):907-18. PubMed ID: 23984893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.